



## J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.

Phone: 022-2482 2222/2493 0918 Fax : 022 – 2493 0534/ 2493 9633

CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

---

### Press Release

---

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, February 3, 2016

### J.B.Chemicals reports robust operating profit growth in Q3.

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on December 31, 2015. The highlights of Y-o-Y results are as under:

(Rs. in crores)

Particulars	Q3-2015-16	Q3-2014-15
Net Sales	270.58	256.81
Operating other income	7.77	6.66
Other Income	12.91	1.96
Total Income	291.26	265.43
EBIDTA	77.87	48.10
EBIT	67.64	37.99
Profit before tax	65.04	35.14
Profit after tax	49.89	24.17
EPS (Rs.) (FV 2)	5.88	2.85

The net sales for the quarter at Rs. 270.58 crores were 5.36% higher compared to net sales in the corresponding quarter in the previous year. The growth in top line was impacted due to overall lower exports. The EBIDTA at Rs. 77.86 crores registered robust growth of 61.89% due to favorable product mix and cost containment. The PBT and PAT for the quarter at Rs. 65.04 crores and Rs. 49.89 crores were Y-o-Y higher both due to higher operating profit as well as higher other income. The other income for the quarter includes Rs. 12.57 crores on account of profit/dividend on investments.

The domestic formulations business at sales of Rs. 102.27 crores registered growth of 17.42%, while the focus products group achieved growth of 21%. The focus on cardiovascular products and topical preparations to drive the growth for the division during the year has met with good success. The contrast media products sales in domestic market at sales of Rs. 8.91 crores registered growth of 13.43%.

The overall formulations exports at Rs. 123.13 crores were 4.88% lower Y-o-Y. The exports for Russia-CIS markets and the Rest of the world markets at Rs. 16.17 crores and Rs. 90.18 crores respectively were lower Y-o-Y due to lower demand and uncertainty in many markets largely due to depreciation of local currency against US \$. The demand in international business still continues to remain sluggish due to currency depreciation issue. Further, Russian ruble too has significantly depreciated against US \$ that will impact performance of the company's Russian subsidiary.

The API sales at Rs. 28.63 crores were 10.77% higher over corresponding quarter in the previous year. The product development income and other sales income during the quarter amounted to Rs. 7.64 crores.

### **Acquisition:**

The company's subsidiary has completed acquisition of 21,94,030 (51%) ordinary shares in Biotech Laboratories (Pty.) Ltd., South Africa ("Biotech"). Post this acquisition, conversion of preference shares and certain fresh issuance of ordinary shares by Biotech, the shareholding of the company's subsidiary in Biotech will be over 95%.

### **About JBCPL:**

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of DMFs and ANDAs. Its State-of-the-Art manufacturing facilities are approved by health authorities of regulated markets.

For more information on JBCPL visit our website at [www.jbcpl.com](http://www.jbcpl.com). For more details, you may contact:

M.C. Mehta  
Company Secretary and Vice President- Compliance  
J. B. Chemicals & Pharmaceuticals Ltd.  
91 22 2482 2311

-- x --

#### *Forward Looking Statements:*

*This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.*